KR930021210A - 레티노이드 수성 겔 조성물 - Google Patents
레티노이드 수성 겔 조성물 Download PDFInfo
- Publication number
- KR930021210A KR930021210A KR1019930006179A KR930006179A KR930021210A KR 930021210 A KR930021210 A KR 930021210A KR 1019930006179 A KR1019930006179 A KR 1019930006179A KR 930006179 A KR930006179 A KR 930006179A KR 930021210 A KR930021210 A KR 930021210A
- Authority
- KR
- South Korea
- Prior art keywords
- aqueous gel
- gel composition
- tretinoin
- skin
- retinoid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 35
- 150000004492 retinoid derivatives Chemical class 0.000 title claims abstract 14
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract 22
- 229960001727 tretinoin Drugs 0.000 claims abstract 22
- 239000002245 particle Substances 0.000 claims abstract 9
- 230000000699 topical effect Effects 0.000 claims abstract 9
- 239000004094 surface-active agent Substances 0.000 claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- 239000003349 gelling agent Substances 0.000 claims 5
- 239000003755 preservative agent Substances 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 230000002335 preservative effect Effects 0.000 claims 4
- 125000005233 alkylalcohol group Chemical group 0.000 claims 3
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 235000006708 antioxidants Nutrition 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000035515 penetration Effects 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229940075529 glyceryl stearate Drugs 0.000 claims 2
- 229920000847 nonoxynol Polymers 0.000 claims 2
- 229940066429 octoxynol Drugs 0.000 claims 2
- 229920002113 octoxynol Polymers 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- -1 allyl ethers Chemical class 0.000 claims 1
- 229940087168 alpha tocopherol Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 229940075582 sorbic acid Drugs 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000036556 skin irritation Effects 0.000 abstract 1
- 231100000475 skin irritation Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
본 발명은 수성 겔 레티노이드 조성물 및 이의 사용방법에 관한 것이다. 보다 특히, 본 발명의 수성 겔 레티노이드 조성물에는 미분화 레티노이드, 특히 트레티노인 입자가 사용되어 피부 자극을 최소화하면서 약제효능이 보유되는 레티노이드의 피부 국소 적용을 위한 수성 겔이 제공된다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (30)
- 치료학적 유효량 미분화 트레티노인 입자, 트레티노인이 피부내로의 투과를 증진시키기에 유효한 양의 계면활성제, 방부제, 신체에 수성 겔 투여 형태를 제공하기에 충분한 양의 겔화제 및 충분량의 물(가하여 100%가 됨)을 포함하는, 트레티노인을 피부에 치료학적 국소 적용하기 위한 트레티노인 수성 겔 조성물.
- 조성물의 총 중량을 기준으로 하여 미분화 트레티노인 입자 0.001 내지 0.5중량%, 계면활성제 0.001 내지 1.0중량%, 방부제 0.005 내지 2.0중량%, 산화방지제 0.01 내지 0.3중량%, 겔화제 1.0 내지 2.0중량%, pH 4.0 내지 7.0범위를 수득하기에 충분한 염기 및 충분량의 물(가하여 100%가 됨)을 포함하는, 트레티노인을 피부에 국소 적용하기 위한 트레티노인 수성 겔 조성물.
- 제1항에 있어서, 계면활성제가 옥톡시놀, 폴리에틸렌 글리콜 글리세릴 스테아레이트 및 노녹시놀로 이루어진 그룹 중에서 선택된 수성 겔 조성물.
- 제1항에 있어서, 방부제가 벤질 알콜, 소르브산, 파라벤, 이미드우레아 및 이들의 배합물로 이루어진 그룹중에서 선택되는 수성 겔 조성물
- 제1항에 있어서, 겔화제가 자당 또는 펜타에리트리톨의 알릴에테르와 가교결합된 아크릴산 중합체 및 폴록사머로 이루어진 그룹중에서 선택되는 수성 겔 조성물.
- 제1항에 있어서, 미분화 트레티노인이 크기가 1내지 30μ 범위인 입자를 90%이상 포함하는 수성 겔 조성물.
- 제1항에 있어서, 미분화 트레티노인 입자의 평균 크기가 1 내지 10μ 범위인 수성 겔 조성물.
- 제1항에 있어서, 폴리비닐피롤리돈이 미분화 트레티노인의 결정 성장을 억제하기에 유효한 양으로 가해진 수성 겔 조성물.
- 제2항에 있어서, 미분화 트레티노인이 0.005 내지 0.2% 범위로 존재하는 수성 겔 조성물.
- 제2항에 있어서, 계면활성제가 0.01 내지 0.5% 범위로 존재하는 수성 겔 조성물.
- 제1항에 있어서, 추가로 킬레이트화제를 포함하는 수성 겔 조성물.
- 제1항에 있어서, 추가로 하이드록시프로필- β-사이클로 덱스트린을 포함하는 수성 겔 조성물.
- 제2항에 있어서, 조성물의 pH를 4.0 내지 7.0으로 감소시키는데 사용되는 염기가 수산화나트륨 또는 트리에탄올아민인 수성 겔 조성물.
- 제1항에 있어서, 조성물의 pH를 4.5 내지 5.5로 하기위해 수산화나트륨이 약 0.1 내지 0.6% 가해진 수성 겔 조성물.
- 제2항에 있어서, 산화방지제가 α- 토코페롤, 부틸화 하이드록시톨루엔, 부틸화 하이드록시아니솔 및 아스코르브산으로 이루어진 그룹중에서 선택되는 수성 겔 조성물.
- 제1항에 있어서, 어떠한 수용성 저급 알킬 알콜도 함유하지 않은 수성 겔 조성물.
- 수성 겔 비히클중의 미분화 트레티노인을 피부의 작용하고자 하는 부위로 전달하는 단계를 포함하여, 피부 국소적용을 위한 트레티노인의 치료 효능을 증가 시키는 방법.
- 제1항에 따른 수성 겔 조성물을 사용하여 미분화 트레티노인을 피부의 적용하고자 하는 부위로 전달하는 단계를 포함하여, 국소적 피부적용을 위한 트레티노인의 치료효능을 증가시키는 방법.
- 제18항에 있어서, 수성 겔 조성물이 수용성 저급 알킬 알콜을 함유하지 않은 방법.
- 미분화 트레티노인을 제1항에 따른 수성 겔 조성물에 도입하는 단계 및 트레티노인 수성 겔을 환자의 피부에 적용하는 단계를 포함하여, 환자의 피부에 국소적으로 적용한 트레티노인의 피부 투과를 증진시키는 방법.
- 미분화 트레티노인을 제1항에 따른 수성 겔 조성물에 도입하는 단계 및 트레티노인 수성 겔을 환자의 피부에 적용하는 단계를 포함하여, 환자에게 트레티노인을 국소 적용시 발생하는 자극을 감소시키는 방법.
- 치료학적 유효량의 미분화 레티노이드 입자, 레티노이드의 피부 내로의 투과를 증진시키기에 유효한 양의 계면활성제, 방부제, 신체에 수성 겔 투여 형태를 제공하기에 충분한 양의 겔화제 조성물 및 충분량의 물(가하여100%가 됨)을 포함하는, 레티노이드를 피부에 치료학적 국소 적용하기 위한 레티노이드 수성 겔 조성물.
- 조성물의 총 중량을 기준으로 하여 미분화 레티노이드 입자 0.0001 내지 0.5중량%, 계면활성제 0.001 내지 1.0중량%, 방부제 0.005 내지 2.0중량%, 산화방지제 0.01 내지 0.3중량%, 겔화제 1.0 내지 2.0중량%, pH 4.0 내지 7.0범위를 수득하기에 충분한 염기 및 충분량의 물(가하여 100%가 됨)을 포함하는, 레티노이드를 피부에 국소 적용하기 위한 레티노이드 수성 겔 조성물.
- 제22항에 있어서, 계면활성제가 옥톡시놀, 폴리에틸렌 글리콜 글리세릴 스테아레이트 및 노녹시놀로 이루어진 그룹중에서 선택되는 수성 겔 조성물.
- 제22항에 있어서, 미분화 레티노이드가 1 내지 30μ 범위인 입자를 90% 이상 포함하는 수성 겔 조성물.
- 제22항에 있어서, 미분화 레티노이드 입자의 평균 크기가 1 내지 10μ 범위인 수성 겔 조성물.
- 제22항에 있어서, 추가로 킬레이트화제를 포함하는 수성 겔 조성물.
- 제23항에 있어서, 킬레이트화제가 에데트산이나트륨 및 시트르산으로 이루어진 그룹중에서 선택되는 수성 겔 조성물.
- 수성 겔 비히클중의 미분화 레티노이드를 피부의 적용하고자 하는 부위로 전달하는 단계를 포함하여, 피부 국소 적용을 위한 레티노이드의 치료 효능을 증가시키는 방법.
- 제29항에 있어서, 수성 겔 비히클이 수용성 저급 알킬 알콜을 함유하지 않는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86968492A | 1992-04-16 | 1992-04-16 | |
| US07/869,684 | 1992-04-16 | ||
| US07/869684 | 1992-04-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR930021210A true KR930021210A (ko) | 1993-11-22 |
| KR970007901B1 KR970007901B1 (ko) | 1997-05-17 |
Family
ID=25354073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019930006179A KR970007901B1 (ko) | 1992-04-16 | 1993-04-14 | 레티노이드 수성 겔 조성물 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5643584A (ko) |
| EP (1) | EP0566405B1 (ko) |
| JP (1) | JP2779303B2 (ko) |
| KR (1) | KR970007901B1 (ko) |
| AT (1) | ATE163540T1 (ko) |
| AU (1) | AU670777B2 (ko) |
| CA (1) | CA2094084C (ko) |
| DE (1) | DE69317139T2 (ko) |
| DK (1) | DK0566405T3 (ko) |
| ES (1) | ES2114588T3 (ko) |
| FI (1) | FI931717A (ko) |
| GR (1) | GR3026597T3 (ko) |
| HU (1) | HUT64468A (ko) |
| IL (1) | IL105413A (ko) |
| MX (1) | MX9302244A (ko) |
| MY (1) | MY111791A (ko) |
| NO (1) | NO303816B1 (ko) |
| NZ (1) | NZ247387A (ko) |
| SG (1) | SG52276A1 (ko) |
| TW (1) | TW429152B (ko) |
| ZA (1) | ZA932653B (ko) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0481007B1 (en) * | 1989-06-07 | 1997-01-22 | BAZZANO, Gail S | SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids |
| AU688757B2 (en) * | 1993-05-27 | 1998-03-19 | Johnson & Johnson Consumer Products, Inc. | Retinoid composition |
| US5646186A (en) * | 1994-05-17 | 1997-07-08 | Johnson & Johnson Consumer Products, Inc. | Retinoid composition |
| FR2718021B1 (fr) * | 1994-04-05 | 1996-06-28 | Fabre Pierre Cosmetique | Composition topique à base de rétinal. |
| ZA954599B (en) * | 1994-06-07 | 1996-01-26 | Allergan Inc | Stable gel formulation for topical treatment of skin conditions |
| US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
| JP3940209B2 (ja) | 1996-11-14 | 2007-07-04 | 株式会社資生堂 | 可溶化化粧料 |
| US6008254A (en) | 1997-05-09 | 1999-12-28 | Kligman; Douglas E. | Method of treating skin disorders with high-strength tretinoin |
| SE9801647D0 (sv) * | 1998-05-12 | 1998-05-12 | Interhealth Ab | Therapeutic composition |
| FR2781371B1 (fr) * | 1998-07-21 | 2001-04-27 | Oreal | Composition cosmetique aqueuse transparente a une seule phase |
| US20020006418A1 (en) * | 1998-10-13 | 2002-01-17 | John Kung | Composition to enhance permeation of topical skin agents |
| US6656456B2 (en) | 1998-11-23 | 2003-12-02 | The Procter & Gamble Company | Skin deodorizing compositions |
| WO2000030599A1 (en) * | 1998-11-23 | 2000-06-02 | The Procter & Gamble Company | Skin deodorizing and sanitizing compositions |
| US6262117B1 (en) * | 1999-02-18 | 2001-07-17 | Allergan Sales, Inc. | Method and composition for treating acne |
| US6114348A (en) * | 1999-03-10 | 2000-09-05 | Weber; Paul J. | Method of treating warts using tazarotene |
| US20030206958A1 (en) * | 2000-12-22 | 2003-11-06 | Cattaneo Maurizio V. | Chitosan biopolymer for the topical delivery of active agents |
| FR2807662A1 (fr) * | 2000-04-12 | 2001-10-19 | Cll Pharma | Procede pour stabiliser la granulometrie d'un principe actif verulent disperse dans un liquide et ses applications |
| WO2001080796A1 (en) * | 2000-04-26 | 2001-11-01 | Watson Pharmaceuticals, Inc. | Minimizing adverse experience associated with oxybutynin therapy |
| US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
| US20040087520A1 (en) * | 2002-10-25 | 2004-05-06 | Chowdhury Dipak K. | Compositions and methods for delivery of therapeutic agents |
| EP1572176A2 (en) * | 2002-12-12 | 2005-09-14 | Galderma Research & Development, S.N.C. | Aqueous-alcoholic depigmenting gel containing a phenolic derivative and a retinoid |
| MXPA05012632A (es) * | 2003-05-20 | 2006-02-22 | Ranbaxy Lab Ltd | Composiciones farmaceuticas de acitretin. |
| US20050112078A1 (en) * | 2003-11-13 | 2005-05-26 | Sekhar Boddupalli | Plant-derived protein extract compositions and methods |
| JP2007536259A (ja) * | 2004-05-06 | 2007-12-13 | イヴレア ファーマスーティカルズ インコーポレイテッド | 活性薬剤の送達のための粒子 |
| US20060141046A1 (en) * | 2004-05-06 | 2006-06-29 | Ivrea Pharmaceuticals, Inc. | Particles for the delivery of active agents |
| US7662855B2 (en) | 2004-05-11 | 2010-02-16 | Imaginative Research Associates, Inc. | Retinoid solutions and formulations made therefrom |
| US20080132580A1 (en) * | 2004-12-17 | 2008-06-05 | Mandavilli Sarveswara Rao Srir | Dispersion For Delivering Active Agents |
| JP2009221164A (ja) | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
| US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
| WO2006068232A1 (ja) * | 2004-12-22 | 2006-06-29 | Sapporo Medical University | 線維化抑制のための薬物担体および薬物担体キット |
| FR2879459B1 (fr) * | 2004-12-22 | 2007-02-16 | Galderma Res & Dev | Composition comprenant de l'adapalene solubilise avec des cyclodextrines |
| US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| JP5342834B2 (ja) * | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
| WO2008001204A2 (en) * | 2006-06-29 | 2008-01-03 | Antares Pharma Ipl Ag | Transdermal compositions of pramipexole having enhanced permeation properties |
| US7803357B2 (en) * | 2006-10-30 | 2010-09-28 | John V Cappello | Topical and transdermal treatments using urea formulation |
| US20090098191A1 (en) * | 2007-10-16 | 2009-04-16 | Anderson Christopher G | Use of bases to stabilize transdermal formulations |
| EP2214661A4 (en) * | 2007-10-18 | 2012-10-03 | Medicis Pharmaceutical Corp | AQUEOUS RETINOID AND BENZOYL PEROXIDE GEL |
| US20100029765A1 (en) * | 2008-07-30 | 2010-02-04 | Ranbaxy Labortories Limited | Topical aqueous composition comprising tretinoin |
| US10022348B2 (en) | 2009-05-20 | 2018-07-17 | Sun Pharmaceutical Industries Limited | Topical solution of isotretinoin |
| SG176097A1 (en) | 2009-05-20 | 2011-12-29 | Ranbaxy Lab Ltd | Topical retinoid solutions |
| US20110117182A1 (en) * | 2009-07-30 | 2011-05-19 | Allergan, Inc. | Combination of dapsone with other anti-acne agents |
| US11419329B2 (en) | 2010-03-12 | 2022-08-23 | Monsanto Technology Llc | Agrochemical gel compositions |
| JP5950428B2 (ja) | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| SG11201405783VA (en) | 2012-03-17 | 2014-10-30 | Univ California | Fast diagnosis and personalized treatments for acne |
| JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| EP3065702B1 (en) | 2013-10-31 | 2023-06-07 | Sun Pharmaceutical Industries Ltd | Topical pharmaceutical composition of acitretin |
| WO2015152332A1 (ja) | 2014-04-02 | 2015-10-08 | 日東電工株式会社 | 標的化分子およびその使用 |
| RU2676680C2 (ru) | 2014-04-07 | 2019-01-10 | Нитто Денко Корпорейшн | Новые гидротропы на основе полимера для доставки гидрофобного лекарственного средства |
| EP3108875A1 (en) * | 2015-06-23 | 2016-12-28 | Galderma Research & Development | Compositions comprising water dispersible nanoparticles of a retinoid compound |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3729568A (en) * | 1969-09-23 | 1973-04-24 | Johnson & Johnson | Acne treatment |
| US3906108A (en) * | 1973-10-12 | 1975-09-16 | Johnson & Johnson | Stabilized tretinoin cream emulsion |
| IN142640B (ko) * | 1975-01-17 | 1977-08-06 | Johnson & Johnson | |
| US4247547A (en) * | 1979-03-19 | 1981-01-27 | Johnson & Johnson | Tretinoin in a gel vehicle for acne treatment |
| DE3119383A1 (de) * | 1981-05-15 | 1982-12-02 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinodpraeparaten |
| US4826871A (en) * | 1985-03-13 | 1989-05-02 | Gressel Philip D | Topical ophthalmic compositions containing one or more retinoids |
| US4966773A (en) * | 1986-11-25 | 1990-10-30 | Alcon Laboratories, Inc. | Topical ophthalmic compositions containing microfine retinoid particles |
| MY105521A (en) * | 1989-04-17 | 1994-10-31 | Healthpoint Ltd | Moisturizing vehicle for topical application of vitamin a acid. |
| US5476852A (en) * | 1989-05-03 | 1995-12-19 | Janssen Pharmaceutica N.V. | Method of topically treating acne vulgaris, hyperkeratotic dermatoses, and photo-aging of the skin |
| FR2647015B1 (fr) * | 1989-05-17 | 1994-05-06 | Cird | Gel aqueux a base d'acide retinoique et son utilisation en medecine humaine et en cosmetique |
| EP0481007B1 (en) * | 1989-06-07 | 1997-01-22 | BAZZANO, Gail S | SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids |
-
1993
- 1993-04-08 AU AU36858/93A patent/AU670777B2/en not_active Expired
- 1993-04-14 NZ NZ247387A patent/NZ247387A/en not_active IP Right Cessation
- 1993-04-14 KR KR1019930006179A patent/KR970007901B1/ko not_active IP Right Cessation
- 1993-04-15 FI FI931717A patent/FI931717A/fi unknown
- 1993-04-15 DK DK93302926T patent/DK0566405T3/da active
- 1993-04-15 ES ES93302926T patent/ES2114588T3/es not_active Expired - Lifetime
- 1993-04-15 DE DE69317139T patent/DE69317139T2/de not_active Expired - Lifetime
- 1993-04-15 SG SG1996001777A patent/SG52276A1/en unknown
- 1993-04-15 MY MYPI93000691A patent/MY111791A/en unknown
- 1993-04-15 NO NO931390A patent/NO303816B1/no not_active IP Right Cessation
- 1993-04-15 JP JP5111186A patent/JP2779303B2/ja not_active Expired - Lifetime
- 1993-04-15 IL IL10541393A patent/IL105413A/en not_active IP Right Cessation
- 1993-04-15 AT AT93302926T patent/ATE163540T1/de active
- 1993-04-15 CA CA002094084A patent/CA2094084C/en not_active Expired - Lifetime
- 1993-04-15 EP EP93302926A patent/EP0566405B1/en not_active Expired - Lifetime
- 1993-04-15 ZA ZA932653A patent/ZA932653B/xx unknown
- 1993-04-16 MX MX9302244A patent/MX9302244A/es unknown
- 1993-04-16 HU HU9301114A patent/HUT64468A/hu unknown
- 1993-05-29 TW TW082104264A patent/TW429152B/zh not_active IP Right Cessation
-
1995
- 1995-05-18 US US08/444,145 patent/US5643584A/en not_active Expired - Lifetime
-
1998
- 1998-04-10 GR GR980400793T patent/GR3026597T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR970007901B1 (ko) | 1997-05-17 |
| SG52276A1 (en) | 1998-09-28 |
| NO303816B1 (no) | 1998-09-07 |
| TW429152B (en) | 2001-04-11 |
| NO931390D0 (no) | 1993-04-15 |
| NZ247387A (en) | 1996-02-27 |
| ES2114588T3 (es) | 1998-06-01 |
| DE69317139T2 (de) | 1998-08-20 |
| AU670777B2 (en) | 1996-08-01 |
| DK0566405T3 (da) | 1998-09-28 |
| FI931717A (fi) | 1993-10-17 |
| AU3685893A (en) | 1993-10-21 |
| IL105413A0 (en) | 1993-08-18 |
| HUT64468A (en) | 1994-01-28 |
| EP0566405A3 (en) | 1993-12-15 |
| ZA932653B (en) | 1994-10-15 |
| GR3026597T3 (en) | 1998-07-31 |
| EP0566405A2 (en) | 1993-10-20 |
| JPH06100443A (ja) | 1994-04-12 |
| US5643584A (en) | 1997-07-01 |
| EP0566405B1 (en) | 1998-03-04 |
| ATE163540T1 (de) | 1998-03-15 |
| CA2094084C (en) | 1998-06-30 |
| JP2779303B2 (ja) | 1998-07-23 |
| CA2094084A1 (en) | 1993-10-17 |
| FI931717A0 (fi) | 1993-04-15 |
| HU9301114D0 (en) | 1993-07-28 |
| NO931390L (no) | 1993-10-18 |
| DE69317139D1 (de) | 1998-04-09 |
| IL105413A (en) | 1999-09-22 |
| MX9302244A (es) | 1994-05-31 |
| MY111791A (en) | 2001-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR930021210A (ko) | 레티노이드 수성 겔 조성물 | |
| US3729568A (en) | Acne treatment | |
| US4387107A (en) | Stable benzoyl peroxide composition | |
| EP0481007B1 (en) | SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids | |
| JP3006888B2 (ja) | メトロニダゾールもしくはメトロニダゾールとクリンダマイシンとの相乗混合物を主成分とする薬剤 | |
| KR930007444A (ko) | 4-비페닐아세트 산(bpaa)를 함유하는 제약학적 조성물 | |
| KR920021139A (ko) | 약학 조성물 | |
| KR910014117A (ko) | 하이드로알콜성 겔을 사용한 이부프로펜의 경피전달 방법 | |
| KR920021140A (ko) | 약학 조성물 | |
| NZ295211A (en) | Topical aqueous gel containing a water-soluble cellulose derivative, propylene glycol & drug(s) for haemorrhoids | |
| ATE15596T1 (de) | Pharmazeutische mittel. | |
| CA2158724A1 (en) | Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid | |
| ES2111102T3 (es) | Formulaciones cosmeticas y dermatologicas con un contenido activo en acido cis-urocaninico. | |
| JPH0327532B2 (ko) | ||
| CA2051621A1 (en) | Oil-in-water type emulsified composition comprising non-steroidal antiphlogistic and analgesic drug | |
| US4699777A (en) | Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea | |
| IE810489L (en) | Composition for topical application | |
| ZA934573B (en) | Preparation for topical use | |
| JPS5750914A (en) | Betamethasone external pharmaceutical | |
| BG48345A1 (en) | Hepatoprotective means |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20121009 Year of fee payment: 16 |
|
| EXPY | Expiration of term |